Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
- JMA Needs to Establish New Partnership with LDP
April 17, 2006
- COMMENTARY 4 articles
April 3, 2006
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- ＜COMMENTARY＞ New Dispensing Fees Nearly Decided
February 20, 2006
- Japan's Most Admired Pharma Companies P. Reed Maurer
February 20, 2006
- Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
February 13, 2006
- Requirements for External IRBs to Be Relaxed
February 13, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
February 6, 2006
- COMMENTARY 2 articles
January 30, 2006
- JPLA SEMINAR
January 30, 2006
- Maurer's Healthcare Insight (72)
January 30, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -2-
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
January 30, 2006
- From "Replacement" to "Addition": Prescription Form
January 23, 2006
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…